{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["46(5)"],"submitter":["Baek JH"],"pubmed_abstract":["<h4>Background</h4>To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in Korean patients with type 2 diabetes mellitus (T2DM).<h4>Methods</h4>Prescription patterns of SGLT2i use between 2015 and 2019 were determined using the Korean National Health Insurance Service database of claims.<h4>Results</h4>Of all patients with T2DM (n=4,736,493), the annual prescription rate of SGLT2i increased every year in patients with ASCVD (from 2.2% to 10.7%) or HF (from 2.0% to 11.1%). After the first hospitalization for ASCVD (n=518,572), 13.7% (n=71,259) of patients initiated SGLT2i with a median of 10.6 months. After hospitalization for HF (n="],"journal":["Diabetes & metabolism journal"],"pagination":["701-712"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9532175"],"repository":["biostudies-literature"],"pubmed_title":["Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease."],"pmcid":["PMC9532175"],"pubmed_authors":["Ko SH","Han KD","Lee BW","Oh TJ","Moon MK","Chon S","Yang YS","Baek JH","Hur KY","Kim JH","Choi JH","Park JS"],"additional_accession":[]},"is_claimable":false,"name":"Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.","description":"<h4>Background</h4>To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in Korean patients with type 2 diabetes mellitus (T2DM).<h4>Methods</h4>Prescription patterns of SGLT2i use between 2015 and 2019 were determined using the Korean National Health Insurance Service database of claims.<h4>Results</h4>Of all patients with T2DM (n=4,736,493), the annual prescription rate of SGLT2i increased every year in patients with ASCVD (from 2.2% to 10.7%) or HF (from 2.0% to 11.1%). After the first hospitalization for ASCVD (n=518,572), 13.7% (n=71,259) of patients initiated SGLT2i with a median of 10.6 months. After hospitalization for HF (n=","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-04T23:19:58.408Z","creation":"2025-04-04T23:19:58.408Z"},"accession":"S-EPMC9532175","cross_references":{"pubmed":["35654585"],"doi":["10.4093/dmj.2022.0002"]}}